Please login to the form below

Not currently logged in
Email:
Password:

Sanofi appoints Diane Souza and Thomas Südhof

They join the board as independent directors

Sanofi has appointed Diane Souza and Thomas Südhof to its board of directors as independent directors, effective 4 May.

Souza brings over 25 years of managed care and health benefits expertise as well as financial management experience to the board. She most recently served as chief executive officer of UnitedHealthcare Speciality Benefits, a voluntary health insurance business.

Prior to this, Souza held the role of chief financial officer at Aetna, overseeing its guaranteed products business, and has also held senior leadership positions at Deloitte and PriceWaterhouseCooper.

Meanwhile, Südhof currently serves as the Avram Goldstein professor and professor of molecular and cellular physiology, psychiatry and neurology at Stanford University's school of medicine.

Before joining Stanford, he spent 25 years at the University of Texas as chairman of the department of neuroscience researching neuro-degenerative and neuro-psychiatric diseases. Südhof was a member of team who won the Nobel Prize in physiology or medicine in 2013.

Serge Weinberg, chairman of Sanofi's board, said: “Both Diane Souza and Thomas Südhof are noted health experts and their great skills make them an outstanding addition to our board.

“We look forward to their contribution to Sanofi's strategy as we continue to innovate and introduce new medicines and vaccines that can help improve health outcomes.”

22nd March 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
TRIDUCIVE

Hello we’re Triducive. We’re a healthcare strategy and value consultancy that provides expert and insight-driven solutions that strengthen and realise...

Latest intelligence

Pandemic preparedness
The pandemic preparedness paradox
Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
Emre Vural
Sourcing R&D innovation: why pharma companies need to evolve their business models
Recent years have seen a significant shift in drug development to specialty areas...
2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...

Infographics